Artivion Inc (AORT)vsEdwards Lifesciences Corp (EW)
AORT
Artivion Inc
$36.12
+1.18%
HEALTHCARE · Cap: $1.73B
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1275% more annual revenue ($6.07B vs $441.33M). EW leads profitability with a 17.7% profit margin vs 2.2%. EW appears more attractively valued with a PEG of 2.14. EW earns a higher WallStSmart Score of 55/100 (C).
AORT
Hold39
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2704.2%
Fair Value
$1.43
Current Price
$36.12
$34.69 premium
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
19.2% revenue growth
Strong operational efficiency at 23.7%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.7% — below average capital efficiency
2.2% margin — thin
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Revenue Growth. Revenue growth of 19.2% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 172.0x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
AORT profiles as a growth stock while EW is a mature play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.64 — expect wider price swings.
AORT is growing revenue faster at 19.2% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 39/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?